Cyrus Biotechnology Integrates DNA/RNA Support into Its Rosetta-based Protein Design Platform

Protein engineering

Home » Emerging technologies » Protein engineering

Collaboration of Four Biotech Companies Showcases High Throughput DNA Assembly Platform for Diverse Applications

May 23, 2019 08:00 AM Eastern Daylight Time – SEATTLE & SAN FRANCISCO–(BUSINESS WIRE)–Arzeda, the Protein Design Company™, Twist Bioscience Corporation (Nasdaq: TWST), TeselaGen Biotechnology Inc...

Codexis Announces CodeEvolver® Technology Transfer and License Agreement with Global Pharmaceutical Leader

Cyrus Biotechnology Announces Release of Antibody Structure Prediction Software for Biologics Drug Development and Discovery

SEATTLE–(BUSINESS WIRE)–Cyrus Biotechnology, Inc., a Seattle-based biotech software company commercializing Rosetta, an advanced protein design platform, announced today the release of a novel Antibody...

Codexis Announces Nestlé Health Science Exercises Option for Exclusive Global License to CDX-6114 for the Management of Phenylketonuria

Codexis Secures Multi-Year Technology Upgrade Package for its CodeEvolver Protein Engineering Platform License with Merck

jewelry

Why the future of protein design rests on cloud computing and machine learning

Evelyn Eggenstein Arbor Biosciences

New cell-free expression system runs on linear DNA

News Digest #244 – A clash of tech titans, and the first Nobel for synthetic biology? Plus, meet Staph epidermidis (sponsored by Conagen)

Frances Arnold

A Nobel Prize for Evolutionary Biology

Arzeda

Arzeda Leverages Scalable Synthetic Biology Resources to Drive Computational Protein Design Platform

Maxygen Appoints Steven B. Riedmuller as Chief Executive Officer

ATUM Receives Patent to Expand and Integrate Transposon Based Technologies for Protein Pharmaceutical Development

UKI2S

UKI2S announces seed investment in Cagen, a pioneering synthetic biology company using protein nanocages

Codexis Appoints Dr. Hicham Alaoui, Veteran Drug Discoverer, as Vice President, Biotherapeutics Research & Development

Codexis Doses First Subjects in Phase 1a Trial of CDX-6114